Get the Stockscreener App
2.68
10.29%
0.25
After Hours:
2.71
0.03
+1.12%
Caribou Biosciences Inc stock is traded at $2.68, with a volume of 2.70M.
It is up +10.29% in the last 24 hours and up +48.07% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$2.43
Open:
$2.44
24h Volume:
2.70M
Relative Volume:
2.11
Market Cap:
$249.57M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.8356
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
+18.58%
1M Performance:
+48.07%
6M Performance:
+239.24%
1Y Performance:
+41.80%
1-Day Range:
$2.40
$2.745
1-Week Range:
$2.17
$2.745
52-Week Range:
$0.66
$2.9995
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.68 | 226.29M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Caribou Biosciences, Inc. $CRBU Shares Sold by Public Employees Retirement System of Ohio - Defense World
Real time social sentiment graph for Caribou Biosciences Inc.Market Growth Summary & Daily Risk Controlled Trade Plans - newser.com
Does Caribou Biosciences Inc. fit your quant trading model2025 Institutional Moves & Growth Focused Stock Pick Reports - newser.com
How to use a screener to detect Caribou Biosciences Inc. breakoutsRate Hike & Community Verified Trade Signals - newser.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Short interest data insights for Caribou Biosciences Inc.July 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - newser.com
Bank of America Securities Sticks to Their Buy Rating for Caribou Biosciences (CRBU) - The Globe and Mail
Combining machine learning predictions for Caribou Biosciences Inc.Trade Signal Summary & Low Risk Entry Point Guides - newser.com
How Caribou Biosciences Inc. stock compares to market leaders2025 Breakouts & Breakdowns & High Conviction Trade Alerts - newser.com
Reversal indicators forming on Caribou Biosciences Inc. stockPortfolio Return Report & Step-by-Step Trade Execution Guides - newser.com
Published on: 2025-10-03 00:57:18 - newser.com
Published on: 2025-10-02 23:00:53 - newser.com
How to monitor Caribou Biosciences Inc. with trend dashboardsJuly 2025 Opening Moves & Pattern Based Trade Signal System - newser.com
CRISPR Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire
CRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight - GlobeNewswire Inc.
BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating - 富途牛牛
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
HC Wainwright Issues Negative Estimate for CRBU Earnings - Defense World
HC Wainwright Expects Lower Earnings for Caribou Biosciences - MarketBeat
Goldman Sachs Group Inc. Has $751,000 Stock Position in Caribou Biosciences, Inc. $CRBU - Defense World
What is HC Wainwright’s Estimate for CRBU FY2026 Earnings? - Defense World
What is HC Wainwright's Estimate for CRBU FY2026 Earnings? - MarketBeat
Will Caribou Biosciences Inc. continue its uptrendTake Profit & AI Driven Price Forecasts - metal.it
Caribou Biosciences stock rating reiterated by H.C. Wainwright - Investing.com India
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Caribou Biosciences Inc Stock (CRBU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCCLUNG BARBARA G | Chief Legal Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
443,502 |
| Khan Ruhi Ahmad | Chief Business Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
66,936 |
| Kanner Steven | Chief Scientific Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
431,556 |
| Ryali Sriram | Chief Financial Officer |
Jan 29 '25 |
Buy |
1.42 |
17,360 |
24,651 |
17,360 |
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):